C. elegans Reproductive Disorder Model for Probiotic Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective model for studying reproductive disorders and screening probiotics to improve reproductive health, particularly in the context of cyclophosphamide-induced reproductive toxicity.
Innovation Solution
A method for constructing a reproductive disorder model using Caenorhabditis elegans (C. elegans) by exposing synchronized L1-stage C. elegans to cyclophosphamide (CTX) in S broth, followed by screening genetically engineered Escherichia coli strains to identify those capable of improving reproductive capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclophosphamide (CTX) is used to treat tumors, then tumor therapeutic effect is improved, but reproductive toxicity increases
Solution Approach 1:
The patent introduces C. elegans as an intermediary model organism to study and screen for probiotics that can mitigate CTX-induced reproductive toxicity. The probiotics act as mediators between CTX and the reproductive system, reducing harmful effects while preserving therapeutic benefits.
Solution Approach 2:
The patent converts the harmful reproductive toxicity of CTX into a beneficial screening opportunity by using the toxicity model to identify probiotics that can protect against reproductive damage, thereby transforming a clinical problem into a solution pathway.
2Productivity
If traditional reproductive disorder models are used, then research capability is limited, but screening efficiency for probiotics is improved using C. elegans
Solution Approach 1:
The patent employs C. elegans, a small, inexpensive, and short-lived organism, as a disposable model system for high-throughput probiotic screening. This allows rapid, cost-effective experimentation without the ethical and logistical constraints of mammalian models.
Solution Approach 2:
The C. elegans model serves multiple functions: it can be used for constructing reproductive disorder models, screening probiotics, studying reproductive mechanisms, and evaluating therapeutic effects, making it a universal platform for reproductive health research.
3Reliability
If genetically engineered probiotic strains are screened, then reproductive health improvement is achieved, but screening process complexity increases
Solution Approach 1:
The patent segments the screening process into distinct stages: constructing the CTX-induced reproductive disorder model, exposing C. elegans to test probiotic strains, and evaluating reproductive outcomes. This segmentation allows systematic evaluation of genetically engineered strains while maintaining manageable complexity.
Data Source
AI summary
The present disclosure provides a method for screening a probiotic strain in promoting reproductive health by using a reproductive disorder model of Caenorhabditis elegans. Cyclophosphamide (CTX) drug intervention is applied to the C. elegans to destroy a normal reproductive system of the C. elegans, thereby obtaining the reproductive disorder model of the C. elegans. Strains capable of significantly improving a reproductive capacity of individuals with reproductive disorders are selected from 3,985 kinds of gene-knockout strains in a Keio gene-knockout library of Escherichia coli; and homologous gene knockout is conducted on a probiotic strain E. coli Nissle 1917 by gene editing, and a probiotic strain with a potential to promote the reproductive health is selected.